A Study on Relapsed b-Cell Lymphoma in Elderly Patient of Bangladeshi Population with Rituximab, Gemcitabin and Oxaliplatin: an Effective Salvage Regimen

High-dose therapy (HDT) with stem-cell support is the reference treatment for relapsed lymphoma, but is not appropriate for all patients. In Bangladesh High-dose therapy with stem cell support is not yet available. Conventional salvage chemotherapies have been used with limited efficacy and significant toxicity. Rituximab, gemcitabin and oxaliplatin are active as single agents in relapsed or refractory lymphoma, and have demonstrated synergistic effects in vitro and in vivo. Twenty two patients with relapsed or refractory or b-cell lymphoma received up to Six cycle of R-GemOx (rituximab 375mg/m2 on day 1, gemcitabine 1000mg/m2 and oxaliplatin 100mg/m2 on day 2). The majority (60%) had diffuse large b-cell lymphoma. After four cycle of R-GemOx, the overall response rate was 90% (45% complete response (CR)/unconfirmed CR (CRu). High CR/CRu rates were observed in all histological subtypes. In patients who had previously received rituximab, the CR/CRu rate after six cycles was 70%. The 2 year event-free and overall survival rates (median follow-up of 24 months) were 55%, respectively, among responders, the probability of being disease free for 2 years was 70%. Treatment was generally well tolerated. R-GemOx shows promising activity with acceptable toxicity in patients with relapsed/refractory b-cell lymphoma. DOI: http://dx.doi.org/10.3329/akmmcj.v5i1.18838 Anwer Khan Modern Medical College Journal Vol. 5, No. 1: January 2014, Pages 29-34

Download Full-text

Phase I Trial of the 131I-Labelled Anti-CD25 Antibody Basiliximab in the Treatment of Patients with Relapsed or Refractory Lymphoma.

Blood ◽

10.1182/blood.v110.11.648.648 ◽

2007 ◽

Vol 110 (11) ◽

pp. 648-648

Author(s):

Gairin Dancey ◽

John Violet ◽

Shokri Othman ◽

Sweta Parker ◽

Alan Green ◽

...

Keyword(s):

Stem Cell ◽

T Cell ◽

Phase I ◽

Cell Lymphoma ◽

Pneumocystis Carinii ◽

High Dose ◽

High Dose Therapy ◽

Stem Cell Support ◽

Dose Therapy ◽

Cell Support

Abstract The survival of patients with Hodgkin lymphoma (HL) has improved over recent decades due to advances in therapy and supportive care. The outcome for patients with relapsed or refractory disease, however, is still unsatisfactory. High dose therapy with stem cell support can salvage many patients but results are poor in patients with chemo-resistant, PET-positive disease pre-transplant. Novel therapies for HL have focused on monoclonal antibodies to antigens such as CD30 but these treatments have produced response rates of only 10% when given as native antibody. Radio-immunotherapy is effective treatment for a range of lymphoproliferative disorders including those that are resistant to other therapies. This phase I study utilised basiliximab, a chimeric antibody to the α-chain of the IL-2 receptor, CD25, conjugated to iodine-131 (131I) in patients with relapsed or refractory lymphomas who were resistant to or intolerant of conventional therapies and who had demonstrable CD25 expression by immunohistochemistry on tissue sections. To determine dose-limiting toxicity an accelerated titration design was used with 6 different doses employed- 370, 740, 1480, 2220 and 2960MBq/m2. Fourteen patients (9M, 5F) with a median age of 38 years (range 28–70) were treated (HL 11 patients, primary mediastinal B-cell lymphoma 1, peripheral T-cell lymphoma NOS 1, adult T-cell leukaemia/lymphoma 1). They had previously received a median of 4 therapies (range 2–8) including autologous stem cell transplant in 9 patients. Five patients were being considered for an autologous or allogeneic stem cell transplantation but had not demonstrated chemosensitivity with standard therapies. All patients were FDG-positive by PET prior to therapy. One patient had a complete response at 740MBq/m2. Six of 9 patients responded to therapy at a dose of 1200MBq/m2 or higher. There were 3 complete responses and 3 partial responses. Two of these patients who had previously not been considered for high dose therapy because of a lack of response have now proceeded to autologous or allogeneic transplant. At a clinically active dose of 1200MBq/m2 the only side effects seen were delayed myelotoxicity; the median platelet count nadir was 31x109/L(range 9–83) and was observed at a median of 38 days (range 33–53) following treatment. Neutropenia (median nadir 1.31x109/L, range 0.9–7.5) was also noted at a median of 53 days (range 37–65) following therapy. One patient was treated at a dose of 2960MBq/m2 and developed prolonged grade 4 neutropenia and thrombocytopenia requiring stem cell support. The patient died of pneumocystis carinii pneumonia. There were no other grade 3 or 4 non-haematologic toxicities noted. The 131I-labelled anti-CD25 antibody basiliximab is well tolerated at doses of 1200MBq/m2 and demonstrates clinical activity at this dose in patients who are refractory to conventional therapies. Further studies are required to determine the long term outcome of patients treated with this agent and to assess its efficacy in the pre-autograft/allograft setting.

Download Full-text